Skip to main content
Erschienen in: International Journal of Legal Medicine 6/2016

07.04.2016 | Original Article

Determination of the unbound fraction of R- and S-methadone in human brain

verfasst von: Karen M. D. Holm, Kristian Linnet

Erschienen in: International Journal of Legal Medicine | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

According to the free drug hypothesis, only the unbound fraction (f u ) of a given drug is biologically available in terms of its pharmacologic activity. Methadone shows large interpersonal variation in toxicity. The goal of the work presented here was to examine whether isolating the unbound fraction of the active R-methadone enantiomer from brain matter could be of value as a forensic tool. A method applying equilibrium dialysis to postmortem brain samples was validated and showed good reproducibility for the previously published f u values for eight common drugs (alprazolam, citalopram, codeine, methadone, morphine, diazepam, oxycodone, tramadol), as well as methadone enantiomers. This method was then applied to approximately 50 authentic case samples with R-methadone and S-methadone concentrations ranging from 0.03 to 13 and 0.6 to 6.8 mg/kg, respectively; median f u values (R-and S-methadone) were 3.9 % (range 3.0–5.3 %) and 3.7 % (range 2.9–4.9 %). No overall correlation between the active R-methadone concentration and f u were found. Small but statistically significant differences in median f u for the R-methadone enantiomer were identified between case-categories (i.e., poisoning with multiple drugs, methadone poisoning, and deaths unrelated to methadone), but these are thought to be too low to be of any forensic value.
Literatur
3.
Zurück zum Zitat de Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JK, van Wilgenburg H, Woodcock BG, Staib AH (1998) L-Methadone and D, L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 4:134–141. doi:10.1159/000018936 CrossRefPubMed de Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JK, van Wilgenburg H, Woodcock BG, Staib AH (1998) L-Methadone and D, L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 4:134–141. doi:10.​1159/​000018936 CrossRefPubMed
5.
Zurück zum Zitat Stimpfl T (2008) Drugs-of-abuse testing in brain. In: Jenkins AJ (ed) Drug testing in alternate biological specimens, 1st edn. Humana Press, Totowa, pp 157–180CrossRef Stimpfl T (2008) Drugs-of-abuse testing in brain. In: Jenkins AJ (ed) Drug testing in alternate biological specimens, 1st edn. Humana Press, Totowa, pp 157–180CrossRef
7.
Zurück zum Zitat Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M (2006) Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos 34:318–323. doi:10.1124/dmd.105.007211 CrossRefPubMed Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M (2006) Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos 34:318–323. doi:10.​1124/​dmd.​105.​007211 CrossRefPubMed
8.
Zurück zum Zitat Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004) Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173:132–138. doi:10.1007/s00213-003-1718-1 CrossRefPubMed Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004) Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173:132–138. doi:10.​1007/​s00213-003-1718-1 CrossRefPubMed
9.
10.
Zurück zum Zitat Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082–2089. doi:10.1002/jps.10453 CrossRefPubMed Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082–2089. doi:10.​1002/​jps.​10453 CrossRefPubMed
11.
Zurück zum Zitat Liu SJ, Roerig DL, Wang RIH (1983) Brain and plasma-levels of methadone and their relationships to analgesic activity of methadone in rats. Drug Metab Dispos 11:335–338PubMed Liu SJ, Roerig DL, Wang RIH (1983) Brain and plasma-levels of methadone and their relationships to analgesic activity of methadone in rats. Drug Metab Dispos 11:335–338PubMed
14.
Zurück zum Zitat Rodriguez-Rosas ME, Medrano JG, Epstein DH, Moolchan ET, Preston KL, Wainer IW (2005) Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. J Chromatogr A 1073:237–248. doi:10.1016/j.chroma.2004.08.153 CrossRefPubMed Rodriguez-Rosas ME, Medrano JG, Epstein DH, Moolchan ET, Preston KL, Wainer IW (2005) Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. J Chromatogr A 1073:237–248. doi:10.​1016/​j.​chroma.​2004.​08.​153 CrossRefPubMed
15.
Zurück zum Zitat Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM (1981) Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 29:211–217. doi:10.1038/clpt.1981.34 CrossRefPubMed Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM (1981) Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 29:211–217. doi:10.​1038/​clpt.​1981.​34 CrossRefPubMed
16.
Zurück zum Zitat Eap CB, Cuendet C, Baumann P (1990) Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 47:338–346. doi:10.1038/clpt.1990.37 CrossRefPubMed Eap CB, Cuendet C, Baumann P (1990) Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 47:338–346. doi:10.​1038/​clpt.​1990.​37 CrossRefPubMed
17.
Zurück zum Zitat Crettol S, Digon P, Golay KP, Brawand M, Eap CB (2007) In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R, S)-methadone, LAAM and their main metabolites. Pharmacology 80:304–311. doi:10.1159/000107104 CrossRefPubMed Crettol S, Digon P, Golay KP, Brawand M, Eap CB (2007) In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R, S)-methadone, LAAM and their main metabolites. Pharmacology 80:304–311. doi:10.​1159/​000107104 CrossRefPubMed
18.
Zurück zum Zitat Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, Wildenboer W, Selby P, Kapur B (2005) Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage? Clin Biochem 38:1088–1094. doi:10.1016/j.clinbiochem.2005.09.009 CrossRefPubMed Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, Wildenboer W, Selby P, Kapur B (2005) Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage? Clin Biochem 38:1088–1094. doi:10.​1016/​j.​clinbiochem.​2005.​09.​009 CrossRefPubMed
21.
Zurück zum Zitat Holm KM, Linnet K (2012) Chiral analysis of methadone and its main metabolite, EDDP, in postmortem brain and blood by automated SPE and liquid chromatography-mass spectrometry. J Anal Toxicol 36:487–496. doi:10.1093/jat/bks057 CrossRefPubMed Holm KM, Linnet K (2012) Chiral analysis of methadone and its main metabolite, EDDP, in postmortem brain and blood by automated SPE and liquid chromatography-mass spectrometry. J Anal Toxicol 36:487–496. doi:10.​1093/​jat/​bks057 CrossRefPubMed
22.
Zurück zum Zitat Diao X, Ma Z, Lei P, Zhong D, Zhang Y, Chen X (2013) Enantioselective determination of 3-n-butylphthalide (NBP) in human plasma by liquid chromatography on a teicoplanin-based chiral column coupled with tandem mass spectrometry. J Chromatogr B 939:67–72. doi:10.1016/j.jchromb.2013.09.014 CrossRef Diao X, Ma Z, Lei P, Zhong D, Zhang Y, Chen X (2013) Enantioselective determination of 3-n-butylphthalide (NBP) in human plasma by liquid chromatography on a teicoplanin-based chiral column coupled with tandem mass spectrometry. J Chromatogr B 939:67–72. doi:10.​1016/​j.​jchromb.​2013.​09.​014 CrossRef
23.
Zurück zum Zitat Zhou T, Zeng J, Liu S, Zhao T, Wu J, Lai W, He M, Xu B, Qu S, Xu L, Tan W (2015) Study on the determination and chiral inversion of R-salbutamol in human plasma and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B 1002:218–227. doi:10.1016/j.jchromb.2015.08.020 CrossRef Zhou T, Zeng J, Liu S, Zhao T, Wu J, Lai W, He M, Xu B, Qu S, Xu L, Tan W (2015) Study on the determination and chiral inversion of R-salbutamol in human plasma and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B 1002:218–227. doi:10.​1016/​j.​jchromb.​2015.​08.​020 CrossRef
24.
26.
27.
Zurück zum Zitat Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606–4615. doi:10.1021/jm070375w CrossRefPubMed Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50:4606–4615. doi:10.​1021/​jm070375w CrossRefPubMed
28.
Zurück zum Zitat Kalvass JC, Maurer TS, Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–666. doi:10.1124/dmd.106.012294 CrossRefPubMed Kalvass JC, Maurer TS, Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660–666. doi:10.​1124/​dmd.​106.​012294 CrossRefPubMed
30.
Zurück zum Zitat Summerfield SG, Stevens AJ, Cutler L, del Carmen OM, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282–1290. doi:10.1124/jpet.105.092916 CrossRefPubMed Summerfield SG, Stevens AJ, Cutler L, del Carmen OM, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282–1290. doi:10.​1124/​jpet.​105.​092916 CrossRefPubMed
31.
Zurück zum Zitat Liu X, Van NK, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–793. doi:10.1124/dmd.108.024125 CrossRefPubMed Liu X, Van NK, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787–793. doi:10.​1124/​dmd.​108.​024125 CrossRefPubMed
32.
Zurück zum Zitat Longhi R, Corbioli S, Fontana S, Vinco F, Braggio S, Helmdach L, Schiller J, Boriss H (2011) Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos 39:312–321. doi:10.1124/dmd.110.036095 CrossRefPubMed Longhi R, Corbioli S, Fontana S, Vinco F, Braggio S, Helmdach L, Schiller J, Boriss H (2011) Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos 39:312–321. doi:10.​1124/​dmd.​110.​036095 CrossRefPubMed
33.
Zurück zum Zitat Banker MJ, Clark TH, Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–974. doi:10.1002/jps.10332 CrossRefPubMed Banker MJ, Clark TH, Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–974. doi:10.​1002/​jps.​10332 CrossRefPubMed
35.
Zurück zum Zitat Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK (2011) Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci 100:2498–2507. doi:10.1002/jps.22452 CrossRefPubMed Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK (2011) Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci 100:2498–2507. doi:10.​1002/​jps.​22452 CrossRefPubMed
36.
Zurück zum Zitat Bjork MK, Simonsen KW, Andersen DW, Dalsgaard PW, Sigurethardottir SR, Linnet K, Rasmussen BS (2013) Quantification of 31 illicit and medicinal drugs and metabolites in whole blood by fully automated solid-phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 405:2607–2617. doi:10.1007/s00216-012-6670-7 CrossRefPubMed Bjork MK, Simonsen KW, Andersen DW, Dalsgaard PW, Sigurethardottir SR, Linnet K, Rasmussen BS (2013) Quantification of 31 illicit and medicinal drugs and metabolites in whole blood by fully automated solid-phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 405:2607–2617. doi:10.​1007/​s00216-012-6670-7 CrossRefPubMed
37.
Zurück zum Zitat Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–338. doi:10.1002/bdd.325 CrossRefPubMed Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–338. doi:10.​1002/​bdd.​325 CrossRefPubMed
38.
Zurück zum Zitat Fridén M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–362. doi:10.1124/dmd.110.035998 CrossRefPubMed Fridén M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–362. doi:10.​1124/​dmd.​110.​035998 CrossRefPubMed
39.
Zurück zum Zitat Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518–1535. doi:10.1080/00498250802499459 CrossRefPubMed Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, Stevens AJ, Metcalf AC, Osuna MC, Kilford PJ, Passchier J, Ruffo AD (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38:1518–1535. doi:10.​1080/​0049825080249945​9 CrossRefPubMed
41.
Zurück zum Zitat Gertz M, Kilford PJ, Houston JB, Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535–542. doi:10.1124/dmd.107.018713 CrossRefPubMed Gertz M, Kilford PJ, Houston JB, Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535–542. doi:10.​1124/​dmd.​107.​018713 CrossRefPubMed
Metadaten
Titel
Determination of the unbound fraction of R- and S-methadone in human brain
verfasst von
Karen M. D. Holm
Kristian Linnet
Publikationsdatum
07.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Legal Medicine / Ausgabe 6/2016
Print ISSN: 0937-9827
Elektronische ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-016-1365-9

Weitere Artikel der Ausgabe 6/2016

International Journal of Legal Medicine 6/2016 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …